



**PHARMACY AND THERAPEUTICS COMMITTEE  
ACA/Exchange MEETING MINUTES  
February 26, 2026**

*Attendance: Microsoft Teams Meeting  
Gary Bledsoe, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director Pharmacy Services; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Hailey Fry, Centennial Pharmacy; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Dr. Merleen Harris-Williams, Medical Director; Yelena Hedrick, Staff/Clinical Pharmacist; Gia Ho, Pharmacy Resident; Jessica (Tran) Hoang-Le, Staff/Clinical Pharmacist; Samantha Jackson, Formulary Pharmacist; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Hannah McCaffrey, Manager Pharmacy Regulations & Implementations; Lisa Murray, Staff/Clinical Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Kateryna Puia, Clinical Programs Pharmacist; Sara Sadiq, Staff/Clinical Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Staff/Clinical Pharmacist; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health; Fallan Vaisberg, Formulary Pharmacist; Jeanine Zubrzycki, Staff/Clinical Pharmacist*

*Excused: Dr. Paul Aitken, Medical Director; Connie Chan, Staff/Clinical Pharmacist; Dr. Demian Elder, Medical Director; Sharon Ford, Staff/Clinical Pharmacist; Ruth John, Staff/Clinical Pharmacist; Brandi Mahler, Supervisor Pharmacy Technicians; Sanjiv Raj, Associate VP Customer Engagement; Julie Samuel, Clinical Programs Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health*

*Minutes taken by: Joana Iverson*

**I. Administrative Update**

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<i>Minutes Review/Approval</i>	<i>D. Dolores presented the minutes from the October 2025 meeting to the Committee for review.</i>	<i>The Committee approved the minutes from our last meeting as presented.</i>	<i>D. Dolores</i>	<i>Resolved</i>
<i>2025 Year in Review</i>	<i>D. Dolores presented the 2025 year in review</i> <ul style="list-style-type: none"> <li><i>• Prior Authorizations</i></li> <li><i>• Top 10 Drugs and Drug Classes</i></li> <li><i>• NCQA - Timeliness Standard</i></li> </ul>		<i>D. Dolores</i>	<i>Informational</i>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<i>2026 Membership Totals</i>	<i>D. Dolores presented the 2026 membership totals</i>		<i>D. Dolores</i>	<i>Informational</i>

## II. 2026 Prior Authorization Updates

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<i>2026 Prior Authorization Criteria Review – no clinical updates</i>	<p><i>The Committee reviewed the 2026 Prior Authorization Criteria. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> <li>• <i>Albendazole</i></li> <li>• <i>Aranesp</i></li> <li>• <i>Brimonidine topical gel</i></li> <li>• <i>Cerdelga</i></li> <li>• <i>CFTR Modulators</i></li> <li>• <i>Chorionic gonadatropin (hCG)</i></li> <li>• <i>Cresemba</i></li> <li>• <i>Cystadane (betaine powder)</i></li> <li>• <i>Dalfampridine</i></li> <li>• <i>Deflazacort</i></li> <li>• <i>Dimethyl Fumarate</i></li> <li>• <i>Epogen-Procrit-Retacrit</i></li> <li>• <i>Fingolimod-Gilenya–Tascenso</i></li> <li>• <i>Increlex</i></li> <li>• <i>Jublia</i></li> <li>• <i>Methyltestosterone</i></li> <li>• <i>Mircera</i></li> <li>• <i>Nitisinone</i></li> <li>• <i>Nuedexta</i></li> <li>• <i>Octreotide</i></li> <li>• <i>Omnipod</i></li> <li>• <i>Orenitram</i></li> <li>• <i>Orilissa</i></li> <li>• <i>Phenoxybenzamine</i></li> <li>• <i>Plegridy</i></li> <li>• <i>Prolia</i></li> <li>• <i>Rezdiffra</i></li> <li>• <i>Rukobia</i></li> <li>• <i>Signifor</i></li> </ul>	<i>The Committee approved as presented.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
	<ul style="list-style-type: none"> <li>• <i>Somavert</i></li> <li>• <i>Sucraid</i></li> <li>• <i>Synarel</i></li> <li>• <i>Tasimelteon</i></li> <li>• <i>Teriflunomide</i></li> <li>• <i>Tobramycin inhalation</i></li> <li>• <i>Tyvaso</i></li> <li>• <i>Vemlidy</i></li> <li>• <i>Vigabatrin</i></li> <li>• <i>Wakefulness Promoting Agents</i></li> </ul>			
<b>2026 Prior Authorization Criteria Updates</b>	<p><i>The Committee reviewed the 2026 Prior Authorization Criteria.</i></p> <ul style="list-style-type: none"> <li>• <i>Adalimumab</i></li> <li>• <i>Albendazole</i></li> <li>• <i>Botulinum Toxins</i></li> <li>• <i>Brimonidine gel</i></li> <li>• <i>Brinsupri (new)</i></li> <li>• <i>Cerdelga</i></li> <li>• <i>CFTR Modulators</i></li> <li>• <i>Chorionic gonadatropin (hCG)</i></li> <li>• <i>Continuous Glucose Monitors</i></li> <li>• <i>Cresemba</i></li> <li>• <i>Dalfampridine</i></li> <li>• <i>GLP-1 Agonists (new)</i></li> <li>• <i>Growth Hormones</i></li> <li>• <i>Haegarda</i></li> <li>• <i>Imcivree</i></li> <li>• <i>Increlex</i></li> <li>• <i>Ingrezza</i></li> <li>• <i>Ivabradine (new)</i></li> <li>• <i>Jascayd (new)</i></li> <li>• <i>Jublia</i></li> <li>• <i>Nexium Esomeprazole packets</i></li> <li>• <i>Nuedexta</i></li> <li>• <i>Octreotide products</i></li> <li>• <i>Omnipod</i></li> <li>• <i>Oral Oncology Agents</i></li> <li>• <i>Orilissa</i></li> <li>• <i>Otezla</i></li> <li>• <i>Palynziq</i></li> </ul>	<p><i>The Committee approved as presented.</i></p>	<p><i>F. Vaisberg H. McCaffrey S. Jackson</i></p>	<p><i>Resolved</i></p>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
	<ul style="list-style-type: none"> <li>• <i>Pegfilgrastim Agents</i></li> <li>• <i>Phenoxybenzamine</i></li> <li>• <i>Posaconazole</i></li> <li>• <i>Pyrimethamine</i></li> <li>• <i>Rezdiffra</i></li> <li>• <i>Rukobia</i></li> <li>• <i>Sapropterin</i></li> <li>• <i>Sepience (new)</i></li> <li>• <i>Signifor</i></li> <li>• <i>Sirturo</i></li> <li>• <i>Somavert</i></li> <li>• <i>Synarel</i></li> <li>• <i>Taltz</i></li> <li>• <i>Tasimelteon</i></li> <li>• <i>Vemlidy</i></li> <li>• <i>Vigabatrin</i></li> <li>• <i>Wainua (new)</i></li> <li>• <i>Wakefulness Promoting Agents</i></li> <li>• <i>Aranesp</i></li> <li>• <i>Cystadane (betaine powder)</i></li> <li>• <i>Cystagon</i></li> <li>• <i>Deflazacort</i></li> <li>• <i>Dimethyl Fumarate</i></li> <li>• <i>Eligard</i></li> <li>• <i>Epogen-Procrit-Retacrit</i></li> <li>• <i>Fidaxomicin</i></li> <li>• <i>Fingolimod - Gilenya - Tascenso</i></li> <li>• <i>Isotretinoin</i></li> <li>• <i>Kevzara</i></li> <li>• <i>Lupron Depot-PED</i></li> <li>• <i>Methyltestosterone</i></li> <li>• <i>Mircera</i></li> <li>• <i>Nitisinone</i></li> <li>• <i>Orenitram</i></li> <li>• <i>Plegridy</i></li> <li>• <i>Prolia</i></li> <li>• <i>Simponi</i></li> <li>• <i>Subcutaneous immune globulin SCIG</i></li> <li>• <i>Sucraid</i></li> <li>• <i>Teriflunomide</i></li> </ul>			

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> <li>• Tobramycin inhalation</li> <li>• Tremfya</li> <li>• Tymlos</li> <li>• Tyvaso</li> <li>• Voriconazole VFEND</li> <li>• Zoledronic Acid (Reclast)</li> <li>• Zometa (zoledronic acid)</li> </ul>			

### III. 2026 Drug Formulary Review/Update

<b>Formulary Additions</b>	<p>The Committee reviewed the Formulary Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> <li>• Besifloxacin hcl 0.6 % suspension - T3</li> <li>• Dropsafe medlance lancet 30g - T3, 200/30 days</li> <li>• Jaythari 22.75 mg/ml suspension - T4, QL 52/30</li> <li>• Kymbee tab - T4, PA, QL 30/30</li> <li>• Loteprednol-tobramycin 0.5-0.3 % suspension - T4</li> <li>• Perampanel 0.5 mg/ml suspension - T4, QL 720/30 days</li> <li>• Shingrix 50 mcg/0.5ml susp prsy - T0</li> <li>• Xyvona tab - T4, PA</li> </ul>	The Committee approved as presented.	F. Vaisberg	Resolved
<b>Formulary Removals</b>	<p>The Committee reviewed the Formulary Removals. The Committee approved as presented.</p> <ul style="list-style-type: none"> <li>• Farxiga - NF (effective 7/1/26)</li> <li>• Xigduo XR - NF (effective 7/1/26)</li> </ul>	The Committee approved as presented.	F. Vaisberg	Resolved
<b>Tier Changes</b>	<p>The Committee reviewed the Tier Changes and approved as presented.</p> <ul style="list-style-type: none"> <li>• Citalopram tablets (10, 20, 40 mg) - Downtier to T1</li> <li>• Escitalopram tablets (5, 10, 20 mg) - Downtier to T1</li> <li>• Fluoxetine capsules (10, 20, 40 mg) - Downtier to T1</li> <li>• Sertraline tablets (25, 50, 100 mg) - Downtier to T1</li> </ul>	The Committee reviewed the Tier Changes and approved as presented.	F. Vaisberg	Resolved
<b>Quantity Limit Additions</b>	<p>The Committee reviewed the Quantity Limit Additions and approved as presented.</p> <ul style="list-style-type: none"> <li>• Brinsupri - 30/30 days</li> <li>• Fluoxetine hcl 10 mg cap - 90/30 days</li> <li>• Fluoxetine hcl 20 mg cap - 120/30 days</li> <li>• Jascayd - 60/30 days</li> <li>• Wainua - 1/28 days</li> </ul>	The Committee reviewed the Quantity Limit Additions and approved as presented.	F. Vaisberg	Resolved

<p><b>IV. New Drug Review</b></p>	<p><i>(Presented in New Drug Review for Medicare.)</i></p> <p><i>The following new Protected Class Drugs were reviewed and will be added to the formulary per CMS regulations:</i></p> <ul style="list-style-type: none"> <li>• <i>Keytruda (pembrolizumab) for Injection</i></li> <li>• <i>Yescarta (axicabtagene ciloleucel) Suspension for Intravenous Infusion</i></li> <li>• <i>Darzalex Faspro (daratumumab and hyaluronidase-fihj) Injection</i></li> <li>• <i>Lunsumio (mosunetuzumab-axgb) Injection</i></li> <li>• <i>Rubraca (rucaparib) Tablets</i></li> <li>• <i>Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) Injection*</i></li> <li>• <i>Enhertu (fam-trastuzumab deruxtecan-nxki) Injection</i></li> <li>• <i>Akeega (abiraterone acetate and niraparib) Tablets</i></li> <li>• <i>Breyanzi (lisocabtagene maraleucel) Suspension for Intravenous Infusion</i></li> <li>• <i>Jaypirca (pirtobrutinib) Tablets</i></li> <li>• <i>Imfinzi (durvalumab) Injection</i></li> <li>• <i>Hyrnuo (sevabertinib) Tablets*</i></li> <li>• <i>Imdelltra (tarlatamab-dlle) for Injection</i></li> <li>• <i>Epkinly (epcoritamab-bysp) Injection</i></li> <li>• <i>Komzifti (ziftomenib) Capsules*</i></li> <li>• <i>Poherdy (pertuzumab-dpzb) Injection*</i></li> <li>• <i>Caplyta (lumateperone) Capsules</i></li> <li>• <i>Revuforj (revumenib) Tablets</i></li> <li>• <i>Blenrep (belantamab mafodotin-blmf) Injection</i></li> <li>• <i>Gazyva (obinutuzumab) Injection</i></li> <li>• <i>Uzedy (risperidone) Extended-Release Injectable Suspension</i></li> <li>• <i>Subvenite (lamotrigine) Oral Suspension*</i></li> <li>• <i>Camcevi (leuprolide mesylate) Injection</i></li> </ul> <p><i>The following medications are Formulary with new FDA-approved indications:</i></p> <ul style="list-style-type: none"> <li>• <i>Nexplanon (etonogestrel) Implant</i></li> <li>• <i>Koselugo (selumetinib) Capsules and Oral Granules</i></li> <li>• <i>Linzess (linaclotide) Capsules</i></li> <li>• <i>Winrevair (sotatercept) for Injection</i></li> <li>• <i>Rybelsus (semaglutide) Tablets</i></li> <li>• <i>Rinvoq (upadacitinib) Extended-Release Tablets</i></li> </ul> <p><i>The following medications were reviewed and will be kept as</i></p>	<p><i>The Committee approved the New Drug Review as presented and recommended.</i></p>	<p><i>G. Ho</i></p>	<p><i>Resolved</i></p>
-----------------------------------	--	--	---------------------	------------------------

	<p><i>Non-formulary. Prior Authorization criteria will be developed as needed:</i></p> <ul style="list-style-type: none"> <li>• <i>Ozempic (semaglutide) Tablets</i></li> <li>• <i>Yuvezzi (brimonidine tartrate and carbachol) Ophthalmic Solution - formerly Brimochol PF*</i></li> <li>• <i>Afrezza (insulin human [rDNA origin]) Inhalation Powder</i></li> <li>• <i>Filkri (filgrastim-laha) Injection*</i></li> <li>• <i>Zycubo (copper histidinate) Injection - formerly CUTX-101*</i></li> <li>• <i>Nereus (tradipitant) Capsules*</i></li> <li>• <i>Yartemlea (narsoplimab-wuug) Injection*</i></li> <li>• <i>Aqvesme (mitapivat) Tablets*</i></li> <li>• <i>Cablivi (caplacizumab-yhdp) Injection</i></li> <li>• <i>Furoscix (furosemide) Injection</i></li> <li>• <i>Wegovy (semaglutide) Tablets</i></li> <li>• <i>Accrufer (ferric maltol) Capsules</i></li> <li>• <i>Jascayd (nerandomilast) Tablets</i></li> <li>• <i>Myqorzo (aficamten) Tablets*</i></li> <li>• <i>Boncrea (denosumab-mobz) Injection*</i></li> <li>• <i>Oziltus (denosumab-mobz) Injection*</i></li> <li>• <i>Nufymco (ranibizumab-leyk) Injection*</i></li> <li>• <i>Exdensur (depemokimab-ulaa) Injection*</i></li> <li>• <i>Fesilty (fibrinogen, human-chmt) Lyophilized Powder for Injection*</i></li> <li>• <i>Addyi (flibanserin) Tablets</i></li> <li>• <i>Cardamyst (etripamil) Nasal Spray*</i></li> <li>• <i>Lerochol (lerodalcibep-liga) Injection*</i></li> <li>• <i>Nuzolvece (zoliflodacin) Granules for Oral Suspension*</i></li> <li>• <i>Orladeyo (berotralstat) Capsules and Oral Pellets</i></li> <li>• <i>Daybue (trofinetide) Oral Solution and Powder for Oral Solution</i></li> <li>• <i>Blujepa (gepotidacin) Tablets</i></li> <li>• <i>Uplizna (inebilizumab-cdon) Injection</i></li> <li>• <i>Waskyra (etuvetidigene autotemcel) Suspension for Intravenous Infusion*</i></li> <li>• <i>Omisirge (omidubicel-only) Suspension for Infusion</i></li> <li>• <i>Avance (acellular nerve allograft-arwx) for Surgical Implantation*</i></li> <li>• <i>Omlyclo (omalizumab-igec) Injection</i></li> <li>• <i>Armlupeg (pegfilgrastim-unne) Injection*</i></li> </ul>			
--	---	--	--	--

	<ul style="list-style-type: none"> <li>• <i>Voyxact (sibeprenlimab-szsi) Injection*</i></li> <li>• <i>Itvisma (onasemnogene abeparvovec-brve) Suspension for Intrathecal Injection*</i></li> <li>• <i>Eylea HD (aflibercept) Injection</i></li> <li>• <i>Redemplo (plozasiran) Injection*</i></li> <li>• <i>Elevidys (delandistrogene moxeparvovec-rokl) Suspension for Intravenous Infusion</i></li> <li>• <i>Kygevvi (doxycitine and doxribtimine) Powder for Oral Solution*</i></li> <li>• <i>Osvyrti (denosumab-desu) Injection*</i></li> <li>• <i>Jubereq (denosumab-desu) Injection*</i></li> <li>• <i>Conexence (denosumab-bnht) Injection</i></li> <li>• <i>Stoboclo (denosumab-bmwo) Injection</i></li> <li>• <i>Lynkuet (elinzanetant) Capsules*</i></li> <li>• <i>Javadin (clonidine hydrochloride) Oral Solution*</i></li> <li>• <i>OmvoH (mirikizumab-mrkz) Injection</i></li> <li>• <i>Contepo (fosfomycin) for Injection*</i></li> <li>• <i>Tezspire (tezpelumab-ekko) Injection</i></li> <li>• <i>Epioxa (riboflavin 5'-phosphate) Ophthalmic Solution*</i></li> <li>• <i>Ferabright (ferumoxytol) Injection*</i></li> </ul> <p>(* Previously discussed in New Drug Review for Medicaid)</p>			
--	--	--	--	--

**V. Adjournment**

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held May 2026.



3/17/2026

---

Danielle Dolores, Director of Pharmacy Services

---

Date